JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

The clinical picture of Eales' disease.

The clinical findings in 316 eyes with Eales' disease and 41 eyes true idiopathic periphlebitis were analyzed. Eales' disease differed clearly from idiopathic periphlebitis in a predominance of male patients, a marked tendency toward bilateral disease in males, the aspect of vascular sheathing and the absence of inflammatory signs from the vitreous body. The clinical picture of Eales' disease was characterized by avascular areas in the retinal periphery, followed posteriorly by microaneurysms, rope-ladder-like dilations of capillary channels, tortousity of neighbouring vessels and spontaneous choriortinal scars. The more pronounced finds were neovascularizations (84%) hemorrhages (58%), obliterated vessels (39%) and vascular sheathing (34%). In contrast to idiopathic periphlebitis, Eales' disease is considered a primary, non-inflammatory disorder of the walls of the peripheral retinal vessels, namely the shunt vessels.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app